

**CHEM****BIO**CHEM

## Supporting Information

© Copyright Wiley-VCH Verlag GmbH & Co. KGaA, 69451 Weinheim, 2009

# Supporting Information

for


## Modification with Organometallic Compounds improves Crossing of the Blood–Brain Barrier of [Leu5]-Enkephalin Derivatives in an in vitro Model System

Antonio Pinto, Ulrich Hoffmanns, Melanie Ott, Gert Fricker, and Nils Metzler-Nolte\*


### Table of Contents

Figures S1 – S6: HPL chromatograms of compounds **3** – **6**, **8** and **9**


Figure S7: Cytotoxicity data for compound **4**




**Figure S1.** Chromatogramm of **3** detection at  $\lambda = 254$  nm




**Figure S2.** Chromatogramm of **4** detection at  $\lambda = 254$  nm.




**Figure S3.** Chromatogramm of **5** detection at  $\lambda = 254$  nm




**Figure S4.** Chromatogramm of **6** detection at  $\lambda = 254$  nm



**Figure S5.** Chromatogramm of **8** detection at  $\lambda = 254$  nm



**Figure S6.** Chromatogramm of **9** detection at  $\lambda = 254$  nm



**Figure S7.** Cytotoxicity of 0.1 mM and 0.7 mM of **4** on the three cancer cell lines HeLa, HepG2 and HT29. Viability was determined by the Resazurin assay. A negative control (culture medium) and a positive control (CisPt = cisplatin) was also tested.